|Day's Range||32.11 - 32.29|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||27.50|
|Dividend & Yield||1.28 (3.98%)|
|1y Target Est||N/A|
The quest has seemed so elusive that it regularly draws comparison to the Holy Grail and unicorns.
Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.
Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.